Navigation Links
Nuvo's High Throughput Experimentation Platform Selected as 2009 Edison Award Finalist
Date:2/24/2009

MISSISSAUGA, ON, Feb. 24 /PRNewswire-FirstCall/ - Nuvo Research Inc. (TSX: NRI), a Canadian drug development company focused on the research and development of drug products delivered to and through the skin using its topical and transdermal drug delivery technologies, today announced that Nuvo's INSIGHT(TM) platform, developed by its San Diego based research and development subsidiary, fqubed, Inc., has been selected as one of four finalists in the Science and Medical category for the prestigious 2009 Edison Best New Product Awards(TM). The awards honour excellence in new product development, marketing, and innovation. Finalists in other categories include the Apple iPhone and Procter & Gamble's Olay Regenerist(R).

Skin-based or transdermal delivery is a sought-after mode of therapeutically administering molecules through the skin and into the body. Skin is a challenging barrier and measuring the effectiveness of multiple formulations' ability to pass through the skin is a prerequisite to developing optimized transdermal and topical treatments. INSIGHT is Nuvo's high throughput experimentation ("HTE") skin permeability screening platform that is 100-times faster than the traditional method of measuring the permeabilizing effect of a drug formulation. INSIGHT's key technological innovation is that it measures skin permeabilization indirectly, via changes in the skin's electrical impedance caused by application of a formulation. This dramatically speeds the measurement process and has allowed fqubed to discover extremely effective molecular penetration enhancer systems.

"This nomination is indicative of the cutting-edge research and development that we are doing at Nuvo Research," said John M. Newsam, fqubed's President and Managing Director. "INSIGHT is being used to accelerate the development of Nuvo's own topical and transdermal drug pipeline and also to open doors with potential partners seeking to co-develop therapeutic products using our HTE skin permeability screening platform."

The Edison Best New Product Awards, sponsored this year by Google, The Nielsen Company and Steelcase, focus on new products and services that excel in marketplace innovation, marketplace success, technological innovation, market structure innovation, and societal impact. These criteria align with Edison's own innovation best practices, called the Five Competencies of Innovation(TM). Gold, Silver and Bronze winners will be announced at an Awards Gala on April 1, 2009 at the Computer History Museum in Mountain View, California. For more information about The Edison Awards, visit www.edisonawards.com.

About Nuvo Research Inc.

Nuvo is focused on the research and development of drug products delivered to and through the skin using its topical and transdermal drug delivery technologies. Nuvo's lead product is Pennsaid, a topical non-steroidal anti-inflammatory drug, used for the treatment of osteoarthritis. Nuvo intends to leverage its skin-penetrating technologies to create a portfolio of topical and transdermal products targeting a variety of indications.

Nuvo Research Inc. is a publicly traded, Canadian pharmaceutical company headquartered in Mississauga, Ontario, with manufacturing facilities in Varennes, Quebec and Wanzleben, Germany and a research and development center in San Diego, California. For more information, please visit www.nuvoresearch.com.

These forward-looking statements, by their nature, necessarily involve risks and uncertainties that could cause actual results to differ materially from those contemplated by the forward-looking statements. The Company considers the assumptions on which these forward-looking statements are based to be reasonable at the time they were prepared, but caution that these assumptions regarding future events, many of which are beyond the control of the Company, may ultimately prove to be incorrect. Factors and risks, which could cause actual results to differ materially from current expectations, are discussed in the annual report, as well as in the Company's Annual Information Form for the year ended December 31, 2007. The Company disclaims any intention or obligation to update or revise any forward-looking statements whether a result of new information or future events, except as required by law. For additional information on risks and uncertainties relating to these forward-looking statements, investors should consult the Company's ongoing quarterly filings, annual report and Annual Information Form and other filings found on SEDAR at www.sedar.com.


'/>"/>
SOURCE Nuvo Research Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. MDS Analytical Technologies Announces Validation of Two More Kits for High-Throughput Detection of Melamine in Food
2. STERRAD(R) CYCLESURE(R) Biological Indicator is now 24 Hours, Accelerating Instrument Throughput
3. Cellectricon Launches Worlds First System for High Throughput RNAi Screening
4. Cold Spring Harbor Protocols features high-throughput methods for analyzing gene activity
5. New Generation Xcelodose(R)S Precision Drug Powder Micro-filling System Offers 50% Increased Throughput
6. Battelle and YuYu Pharma Create the First Joint Bioequivalence Test Experimentation Institution
7. Call-Shadow IP Call Management Software Now With Increased Platform Support
8. Frost & Sullivan Recognizes WCC for Its Unique Multimodal Platform
9. Edge Health Solutions Selects Allscripts Electronic Health Record for Apple Mac OS X Medical Platform
10. Accordent Delivers Medical Lecture Capture Platform for University of Texas Health Sciences Center
11. Sciton Unveils the JOULE Aesthetic Laser Platform for Physicians Battling the Economic Squeeze
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... ... , ... Quality metrics are proliferating in cancer care, and are derived from ... of the beholder, according to experts who offered insights and commentary in the current ... For the full issue, click here . , For the American Society of ...
(Date:6/26/2016)... ... June 26, 2016 , ... PawPaws brand pet supplements owned ... developed to enhance the health of felines. The formula is all-natural and is made ... in the PawPaws Cat Kidney Support Supplement Soft Chews are Astragalus Root ...
(Date:6/25/2016)... Washington, D.C. (PRWEB) , ... June 25, 2016 ... ... will discuss health policy issues and applications at AcademyHealth’s Annual Research Meeting June ... share their work on several important health care topics including advance care planning, ...
(Date:6/25/2016)... ... June 25, 2016 , ... "With 30 hand-drawn hand gesture animations, FCPX ... Austin - CEO of Pixel Film Studios. , ProHand Cartoon’s package transforms over ... Cut Pro X . Simply select a ProHand generator and drag it above media ...
(Date:6/25/2016)... ... June 25, 2016 , ... Dr. Calvin Johnson has ... he has implemented orthobiologic procedures as a method for treating his patients. The ... first doctors to perform the treatment. Orthobiologics are substances that orthopaedic surgeons use ...
Breaking Medicine News(10 mins):
(Date:6/26/2016)... -- One of Australia,s successful biotechnology scientists, ... new biotechnology company, Noxopharm Limited [ABN 50 608 966 123] ("Noxopharm"). ... list on the ASX. Noxopharm is a clinic-ready company ... Phase 1 clinical study later this year. ... biggest problems facing cancer patients - the ability of cancers to ...
(Date:6/26/2016)... -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ ) ... Improvements Act of 1976, as amended ("HSR"), with respect ... Nasdaq: CPXX ) expired effective June 24, ... As previously announced on May 31, 2016, Jazz Pharmaceuticals ... which Jazz Pharmaceuticals has commenced a tender offer for ...
(Date:6/26/2016)... , June 27, 2016  VMS Rehab Systems, ... Board will take whatever measures required to build a ... stock which is currently listed on the OTC Markets-pink ... Company Chairman and CEO, "We are seeing an anomaly ... to understand, not only by the Company, but shareholders ...
Breaking Medicine Technology: